VivoSeq
Neurology

Generalized Myasthenia Gravis

10

Pipeline Programs↗

12

Active Trials↗

8

Companies Involved↗

Generalized Myasthenia Gravis is an early-stage landscape with 10 programs across 8 companies. The most active players are Argenx, Horizon Therapeutics Ireland DAC, UCB. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Argenx logo

Argenx

1 program

Phase 2H

Horizon Therapeutics Ireland DAC

1 program

Phase 2UCB logo

UCB

2 programs

Phase 3Merck & Co. logo

Merck & Co.

2 programs

Phase 3Regeneron logo

Regeneron

2 programs

Phase 3Novartis logo

Novartis

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

8programs
Monoclonal antibody450%
Small molecule338%
RNA therapy113%

Modality classified for 90% of 10 pipeline programs.

Analysis

Trial Status

12

clinical trials

Recruiting5 · 42%
Active, not recruiting3 · 25%
Enrolling by invitation2 · 17%
Not yet recruiting2 · 17%

Clinical Trials

Trial Activity

12 trials

A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Generalized Myasthenia Gravis (gMG)
Recruiting·Amgen logoAmgen·Phase 2·NCT06987539·15 enrolled
A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
Recruiting·UCB logoUCB·Preclinical·NCT06055959·8 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06463587·264 enrolled
An Open-label, Multi-center, Phase I/II Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Participants With Treatment-resistant Generalized Myasthenia Gravis
Recruiting·Novartis logoNovartis·Preclinical·NCT06704269·15 enrolled
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Iptacopan in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
Recruiting·Novartis logoNovartis·Phase 3·NCT06517758·146 enrolled
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis
Active, not recruiting·Regeneron logoRegeneron·Phase 3·NCT05070858·288 enrolled
An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Active, not recruiting·UCB logoUCB·Preclinical·NCT06149559·12 enrolled
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Active, not recruiting·UCB logoUCB·Phase 3·NCT04225871·200 enrolled
ISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Not yet recruiting·Argenx logoArgenx·Phase 2·NCT07673627·40 enrolled
An Open-label, Single-arm, Multi-center, Interventional Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adult Patients With Generalized Myasthenia Gravis (gMG)
Not yet recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07596784·20 enrolled
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
Enrolling by invitation·UCB logoUCB·Phase 3·NCT06435312·8 enrolled
An Open-label Extension Study to Evaluate Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
Enrolling by invitation·UCB logoUCB·Phase 3·NCT06540144·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)